CatJourney
Active member
I see a lot of questions lately about peptides that are not GLP-1s but tend to come up in the same circles: mitochondrial “energy” stacks (SS-31, MOTS-c, NAD+), cognitive peptides like Cerebrolysin, growth hormone secretagogues (ipamorelin, tesamorelin, etc.), and healing peptides (BPC-157 / TB-500).
This is a consolidated overview based on community discussions, clinical data where available, and practical experience shared by users. As always: most of these are NOT FDA-approved for general wellness or anti-aging, quality control varies widely, and long-term human data are limited.
1) MITOCHONDRIAL / “ENERGY” STACKS: SS-31, MOTS-c, NAD+
These are often grouped together under a “mitochondrial optimization” or “fatigue protocol.” The theory: improve mitochondrial function → improve cellular energy production → improve fatigue, performance, and possibly metabolic health.
SS-31 (also known as elamipretide)
• Mechanism: Targets cardiolipin in the inner mitochondrial membrane. The idea is to stabilize and improve mitochondrial efficiency.
• Research: Studied in mitochondrial myopathies and cardiac conditions. Not broadly approved for general fatigue.
• Typical community use: Short cycles (for example, several weeks) rather than indefinite use.
Many protocols "prime" with SS-31 first, based on the logic that you repair or stabilize mitochondria before layering on agents that stimulate energy pathways.
MOTS-c
• Mechanism: A mitochondrial-derived peptide thought to influence metabolic pathways, insulin sensitivity, and exercise adaptation.
• Often described as performance-enhancing in effect.
• Usually cycled, not taken indefinitely.
Some community protocols introduce MOTS-c later in a 12–14 week structure, after SS-31 and NAD+ have been started.
NAD+ (or NAD precursors like NR/NMN)
• NAD+ is a central cofactor in cellular energy metabolism.
• Levels decline with age.
• Forms used: injectable NAD+, oral precursors like NR (nicotinamide riboside) or NMN.
User experience varies a lot:
Important perspective: NAD-related effects tend to be subtle. Many long-term users of oral NR say they only notice a difference when they stop.
Example of a Structured 14-Week Protocol (Community Style)
While variations exist, the general idea is:
Key considerations:
• Sleep tracking is helpful. Some users report lighter sleep initially.
• Do not expect stimulant-like effects.
• Evaluate fatigue objectively (morning energy, workout performance, resting heart rate, HRV if available).
There is no consensus that you need to stay on MOTS-c forever. A more conservative approach some experienced users suggest:
2) CEREBROLYSIN (Cognitive / Neurotrophic Peptide Mix)
Cerebrolysin is a peptide mixture derived from porcine brain tissue and used in some countries for stroke and neurodegenerative conditions.
Important distinction:
• Authentic Cerebrolysin comes in ampules at a high mg/mL concentration.
• Lyophilized “cerebroprotein” products are not the same thing.
Typical Community Cycle Example:
• Start low (for example, 1 mL IM daily, 5 days on / 2 days off) to assess tolerance.
• Increase to 5 mL IM daily, 5 days on / 2 days off.
• Duration: 4–6 weeks total.
Reported benefits:
Practical tips often shared:
• Use a filter when drawing from glass ampules to avoid glass particles.
• Protect from light (light-sensitive).
• Refrigerate once drawn into syringes.
This is an IM protocol for most users. Volume matters: 5 mL IM is significant and may require appropriate needle selection and injection site rotation.
Risks and unknowns:
• Limited long-term safety data in healthy individuals.
• Possible agitation, sleep disturbance, or overstimulation in some.
• Injection-related risks.
3) GROWTH HORMONE SECRETAGOGUES: IPAMORELIN & TESAMORELIN
These stimulate endogenous growth hormone (GH) release rather than supplying GH directly.
Ipamorelin
• Ghrelin receptor agonist.
• Stimulates GH release with less effect on cortisol and prolactin compared to older GHRPs.
• Sometimes prescribed for low IGF-1 levels.
Example dosing discussed in clinical settings:
• ~300–350 mcg injected before bed daily.
Why bedtime?
• GH is naturally secreted in pulses during early sleep.
• Mimics physiologic rhythm.
Potential benefits:
But:
• Effects can be modest.
• Cost vs. benefit is variable.
• Lab monitoring (IGF-1) is recommended.
Tesamorelin
• FDA-approved (brand indication) for reducing visceral fat in HIV-associated lipodystrophy.
• Dose in that setting: 2 mg daily.
• Reduced visceral fat significantly over ~26 weeks in studies.
For “run-of-the-mill” TRT patients:
• No direct head-to-head comparisons among secretagogues.
• Access and cost are major limiting factors.
• Off-label aesthetic or metabolic use lacks robust comparative data.
Other related agents sometimes mentioned:
• Sermorelin
• GHRP-2
• Ibutamoren (oral GH secretagogue)
All share similar caveats: variable quality (outside prescription channels), water retention risk, insulin sensitivity concerns, and need for lab monitoring.
4) BPC-157 & TB-500 (Injury / Tissue Healing)
Often called the “Wolverine stack” in online communities.
BPC-157
• Synthetic fragment of a gastric peptide.
• Animal data suggest enhanced tendon, ligament, and soft tissue healing.
• Common community dose: 250–500 mcg daily, often injected near injury site.
TB-500 (Thymosin Beta-4 analog)
• Involved in actin regulation and cell migration.
• Often dosed in milligrams rather than micrograms.
• Community protocols vary widely (for example, 2–5 mg per injection, weekly or multiple times weekly during a loading phase).
User-reported outcomes:
Example shared pattern:
• Several mg TB-500 split across injections over 2–3 weeks.
• Noticeable improvement after second injection.
• Additional vials needed for full resolution.
Cautions:
• Most evidence is preclinical (animal).
• Quality control is a serious concern.
• Overly aggressive dosing increases cost without proven added benefit.
COMMON THEMES ACROSS ALL THESE PEPTIDES
1) Expectations matter.
These are not caffeine, amphetamines, or GLP-1s with dramatic appetite effects. Many effects are subtle.
2) Cycles vs. indefinite use.
• SS-31, MOTS-c, Cerebrolysin, TB-500 are usually cycled.
• NAD precursors and some GH secretagogues may be used longer-term, but require labs and reassessment.
3) Sleep can change.
• NAD+ and Cerebrolysin may alter sleep patterns initially.
• GH secretagogues can improve or disrupt sleep depending on timing and dose.
4) Labs are your friend.
For GH-related peptides:
For fatigue protocols:
Always rule out basics before assuming you need a mitochondrial peptide.
WHO SHOULD BE CAUTIOUS OR AVOID?
• Active cancer or history of hormone-sensitive malignancy (especially GH-related peptides).
• Uncontrolled diabetes (GH secretagogues can worsen glycemic control).
• Psychiatric instability (Cerebrolysin may affect mood or stimulation levels).
• Pregnancy or breastfeeding.
FINAL THOUGHTS
There is a big difference between:
• Clinically studied, indication-specific use (e.g., tesamorelin for HIV-related visceral fat)
vs.
• Biohacker-style protocols for energy, longevity, or performance.
If you are fatigued, injured, or cognitively foggy, start with:
Then consider peptides as adjuncts, not magic bullets.
Happy to answer questions or break down any one of these in more detail.
This is a consolidated overview based on community discussions, clinical data where available, and practical experience shared by users. As always: most of these are NOT FDA-approved for general wellness or anti-aging, quality control varies widely, and long-term human data are limited.
1) MITOCHONDRIAL / “ENERGY” STACKS: SS-31, MOTS-c, NAD+
These are often grouped together under a “mitochondrial optimization” or “fatigue protocol.” The theory: improve mitochondrial function → improve cellular energy production → improve fatigue, performance, and possibly metabolic health.
SS-31 (also known as elamipretide)
• Mechanism: Targets cardiolipin in the inner mitochondrial membrane. The idea is to stabilize and improve mitochondrial efficiency.
• Research: Studied in mitochondrial myopathies and cardiac conditions. Not broadly approved for general fatigue.
• Typical community use: Short cycles (for example, several weeks) rather than indefinite use.
Many protocols "prime" with SS-31 first, based on the logic that you repair or stabilize mitochondria before layering on agents that stimulate energy pathways.
MOTS-c
• Mechanism: A mitochondrial-derived peptide thought to influence metabolic pathways, insulin sensitivity, and exercise adaptation.
• Often described as performance-enhancing in effect.
• Usually cycled, not taken indefinitely.
Some community protocols introduce MOTS-c later in a 12–14 week structure, after SS-31 and NAD+ have been started.
NAD+ (or NAD precursors like NR/NMN)
• NAD+ is a central cofactor in cellular energy metabolism.
• Levels decline with age.
• Forms used: injectable NAD+, oral precursors like NR (nicotinamide riboside) or NMN.
User experience varies a lot:
- Some report “clean” energy and reduced caffeine need.
- Others report nothing noticeable but believe it works subtly.
- A few report sleep changes (sometimes worse sleep early on).
Important perspective: NAD-related effects tend to be subtle. Many long-term users of oral NR say they only notice a difference when they stop.
Example of a Structured 14-Week Protocol (Community Style)
While variations exist, the general idea is:
- Weeks 1–4: Emphasis on SS-31 + NAD+
- Mid-phase: Gradual addition of MOTS-c
- Final weeks: MOTS-c + NAD+ together
Key considerations:
• Sleep tracking is helpful. Some users report lighter sleep initially.
• Do not expect stimulant-like effects.
• Evaluate fatigue objectively (morning energy, workout performance, resting heart rate, HRV if available).
There is no consensus that you need to stay on MOTS-c forever. A more conservative approach some experienced users suggest:
- Daily oral NR/NMN for maintenance
- Periodic SS-31 cycles for “mitochondrial tune-ups”
- MOTS-c as a performance-focused cycle rather than baseline therapy
2) CEREBROLYSIN (Cognitive / Neurotrophic Peptide Mix)
Cerebrolysin is a peptide mixture derived from porcine brain tissue and used in some countries for stroke and neurodegenerative conditions.
Important distinction:
• Authentic Cerebrolysin comes in ampules at a high mg/mL concentration.
• Lyophilized “cerebroprotein” products are not the same thing.
Typical Community Cycle Example:
• Start low (for example, 1 mL IM daily, 5 days on / 2 days off) to assess tolerance.
• Increase to 5 mL IM daily, 5 days on / 2 days off.
• Duration: 4–6 weeks total.
Reported benefits:
- Improved verbal fluency
- Reduced brain fog
- Better mood stability
- Possible improvement in tinnitus (anecdotal)
Practical tips often shared:
• Use a filter when drawing from glass ampules to avoid glass particles.
• Protect from light (light-sensitive).
• Refrigerate once drawn into syringes.
This is an IM protocol for most users. Volume matters: 5 mL IM is significant and may require appropriate needle selection and injection site rotation.
Risks and unknowns:
• Limited long-term safety data in healthy individuals.
• Possible agitation, sleep disturbance, or overstimulation in some.
• Injection-related risks.
3) GROWTH HORMONE SECRETAGOGUES: IPAMORELIN & TESAMORELIN
These stimulate endogenous growth hormone (GH) release rather than supplying GH directly.
Ipamorelin
• Ghrelin receptor agonist.
• Stimulates GH release with less effect on cortisol and prolactin compared to older GHRPs.
• Sometimes prescribed for low IGF-1 levels.
Example dosing discussed in clinical settings:
• ~300–350 mcg injected before bed daily.
Why bedtime?
• GH is naturally secreted in pulses during early sleep.
• Mimics physiologic rhythm.
Potential benefits:
- Increased IGF-1
- Improved recovery
- Possible joint/connective tissue support
- Improved sleep in some users
But:
• Effects can be modest.
• Cost vs. benefit is variable.
• Lab monitoring (IGF-1) is recommended.
Tesamorelin
• FDA-approved (brand indication) for reducing visceral fat in HIV-associated lipodystrophy.
• Dose in that setting: 2 mg daily.
• Reduced visceral fat significantly over ~26 weeks in studies.
For “run-of-the-mill” TRT patients:
• No direct head-to-head comparisons among secretagogues.
• Access and cost are major limiting factors.
• Off-label aesthetic or metabolic use lacks robust comparative data.
Other related agents sometimes mentioned:
• Sermorelin
• GHRP-2
• Ibutamoren (oral GH secretagogue)
All share similar caveats: variable quality (outside prescription channels), water retention risk, insulin sensitivity concerns, and need for lab monitoring.
4) BPC-157 & TB-500 (Injury / Tissue Healing)
Often called the “Wolverine stack” in online communities.
BPC-157
• Synthetic fragment of a gastric peptide.
• Animal data suggest enhanced tendon, ligament, and soft tissue healing.
• Common community dose: 250–500 mcg daily, often injected near injury site.
TB-500 (Thymosin Beta-4 analog)
• Involved in actin regulation and cell migration.
• Often dosed in milligrams rather than micrograms.
• Community protocols vary widely (for example, 2–5 mg per injection, weekly or multiple times weekly during a loading phase).
User-reported outcomes:
- Reduced joint pain after 1–2 weeks
- Improved range of motion
- Faster recovery from chronic tendon issues
Example shared pattern:
• Several mg TB-500 split across injections over 2–3 weeks.
• Noticeable improvement after second injection.
• Additional vials needed for full resolution.
Cautions:
• Most evidence is preclinical (animal).
• Quality control is a serious concern.
• Overly aggressive dosing increases cost without proven added benefit.
COMMON THEMES ACROSS ALL THESE PEPTIDES
1) Expectations matter.
These are not caffeine, amphetamines, or GLP-1s with dramatic appetite effects. Many effects are subtle.
2) Cycles vs. indefinite use.
• SS-31, MOTS-c, Cerebrolysin, TB-500 are usually cycled.
• NAD precursors and some GH secretagogues may be used longer-term, but require labs and reassessment.
3) Sleep can change.
• NAD+ and Cerebrolysin may alter sleep patterns initially.
• GH secretagogues can improve or disrupt sleep depending on timing and dose.
4) Labs are your friend.
For GH-related peptides:
- IGF-1
- Fasting glucose
- A1C
- Lipids
For fatigue protocols:
- Thyroid panel
- Ferritin
- B12
- Vitamin D
- Testosterone (if applicable)
Always rule out basics before assuming you need a mitochondrial peptide.
WHO SHOULD BE CAUTIOUS OR AVOID?
• Active cancer or history of hormone-sensitive malignancy (especially GH-related peptides).
• Uncontrolled diabetes (GH secretagogues can worsen glycemic control).
• Psychiatric instability (Cerebrolysin may affect mood or stimulation levels).
• Pregnancy or breastfeeding.
FINAL THOUGHTS
There is a big difference between:
• Clinically studied, indication-specific use (e.g., tesamorelin for HIV-related visceral fat)
vs.
• Biohacker-style protocols for energy, longevity, or performance.
If you are fatigued, injured, or cognitively foggy, start with:
- Sleep
- Nutrition
- Micronutrient status
- Thyroid and sex hormones
- Training load
Then consider peptides as adjuncts, not magic bullets.
Happy to answer questions or break down any one of these in more detail.